繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


体彩p5中奖新闻 山西快乐十分开奖时间表 体彩11选5规则及奖金 配资公司平台一卓信宝配资23 七星彩网上投注平台 双色球开奖结果双今天 000158股吧 天津快乐十分前三组 tcl股票行情分析 贵州快3和值走势图表 哪有快乐10分的走势图